BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Jun 25, 2012
 |  BioCentury  |  Analyst Picks & Changes

Analyst picks and changes

Analyst picks and changes

Company Bank Analyst Coverage Opinion Wk chg 6/22 cls
Celgene Corp. (NASDAQ:CELG) Baird Christopher Raymond Price target Outperform -7% $61.63
Barclays Capital Ying Huang Price target Overweight
Jefferies Thomas Wei Price target Buy
RBC Capital Markets Michael Yee Downgrade Sector perform (from outperform)
Summer Street Carol Werther Price target Buy
Raymond lowered his target to $78 from $81 after Celgene withdrew a European application to extend the label for Revlimid lenalidomide to include front-line maintenance treatment for multiple myeloma (MM) (see...

Read the full 847 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >